“ Meaningful antitumor activity observed in recurrent/metastatic HRAS mutant HNSCC, including CR “ “ Data validate activity of farnesyltransferase inhibitors and support rapid advancement of KO-2806...
Kura Oncology is axing all but one clinical development program involving an old Janssen candidate.
SAN DIEGO, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported proof of mechanism in KURRENT-HN, the Company’s Phase 1/2 clinical trial of tipifarnib in combination with alpelisib in patients with HRAS- and/or PIK3CA-dependent head and neck squamous cell carcinoma (HNSCC). The preliminary data are being presented at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium in Barcelona.
SAN DIEGO, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Kura nOncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical ncompany committed to realizing the promise of precision medicines for nthe treatment of cancer, today announced dose administration for the nfirst patient in KURRENT, the Company’s Phase 1/2 clinical trial of ntipifarnib in combination with alpelisib in patients with HRAS- and/or nPIK3CA-dependent head and neck squamous cell carcinoma (HNSCC).
SAN DIEGO, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. n(Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to nrealizing the promise of precision medicines for the treatment of ncancer, today announced final results from a Phase 2 study of tipifarnibnas a monotherapy in patients with relapsed or refractory T-cell nlymphoma, including an overall response rate (ORR) of 56% and a median noverall survival of 32.8 months in heavily pretreated patients with nangioimmunoblastic T-cell lymphoma (AITL).
Protagonist Announces Plans to Initiate a Global Phase 3 Study for Rusfertide in Polycythemia Vera Following Interactions with the U.S. Food & Drug Administration and the European Medicines Agency
SAN DIEGO, March 22, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the publication of results from its RUN-HN study, a Phase 2 open-label, single-arm trial of tipifarnib in patients with HRAS mutant head and neck squamous cell carcinoma (HNSCC) whose disease had progressed after prior therapy. The paper, titled “Tipifarnib in Head and Neck Squamous Cell Carcinoma with HRAS Mutations,” was published online in the Journal of Clinical Oncology earlier today.
SAN DIEGO, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that its investigational drug, tipifarnib, has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with recurrent or metastatic HRAS mutant head and neck squamous cell carcinoma (HNSCC) with variant allele frequency ? 20% after disease progression on platinum-based chemotherapy. Tipifarnib is currently being evaluated in an ongoing registration-directed clinical trial (AIM-HN) in this indication of high unmet need.
SAN DIEGO, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, reported new preclinical data demonstrating the Company’s late-stage drug candidate, tipifarnib, shows compelling activity when combined with a PI3K? inhibitor in models of HRAS/PI3K-dysregulated head and neck squamous cell carcinoma (HNSCC), including tumors with PIK3CA mutations or amplifications as well as HRAS overexpression.
Troy Wilson was working with J&J on their KRAS inhibitor and periodically thumbing through their publications when he spotted an old drug called tipifarnib that looked promising. So promising, in fact, that the large pharma had run it through over 5,000 patients across 70 trials, hoping they would at some point be able to nail down who were the small slice of patients who responded in some studies.